US › Healthcare

Cyclerion Therapeutics Inc (CYCN)

US · Healthcare · Biotechnology

$3.51+0.57%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-3.2M
Profit YoY
-122.3%
EPS
$-0.19
EPS estimate
$-0.38

EPS came in at -0.19 against a street estimate of -0.38 — a beat of 50.0%.

Key statistics

Market cap
$15.2M
Forward P/E
0.0
P/B
2.23
Book value
$1.60
EPS (TTM)
$-1.31
52-week high
$8.48
52-week low
$1.03
50-day MA
$3.33
200-day MA
$2.29
Beta
1.75

Analyst view

Analysts rate Cyclerion Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $8.00.

Shareholding

Insiders
21.02%
Institutions
3.99%

Largest institutional holders

FundStake
Geode Capital Management, LLC1.95%
Two Sigma Advisers, LLC0.65%
Vanguard Group Inc0.54%
Citadel Advisors Llc0.42%
BlackRock Inc0.39%
Vanguard Capital Management, LLC0.37%
Kovack Advisors Inc0.23%
Vanguard Fiduciary Trust Co0.17%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Cyclerion Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.